Table 2.

Cumulative 5-year clinical and cost outcomes of F/TAF compared to F/TDF among MSM in the US^*

		F/TAF Outcomes		F/TDF Outcomes
Age group (years)	# on PrEP	QALYs	Costs ($)	Excess cases of ESRD	Excess fractures	QALYs	Costs ($)	ICER ($Δ/ΔQALYs)
13–24	16,069	80,344	1,333,700,000	0.2	128	80,305	675,930,000	16,960,000
25–34	49,442	247,210	4,103,700,000	2	393	247,090	2,080,600,000	16,380,000
35–44	28,429	142,150	2,359,600,000	5	764	141,910	1,235,800,000	4,681,200
45–54	19,777	98,884	1,641,500,000	7	568	98,698	863,930,000	4,163,500
55+	9,888	49,442	820,740,000	11	250	49,341	433,240,000	3,836,700
Total**	123,610	618,030	10,259,000,000	25	2,101	617,340	5,289,500,000	7,201,200

F/TAF: tenofovir alafenamide/emtricitabine; F/TDF: tenofovir disoproxil fumarate/emtricitabine; PrEP: pre-exposure prophylaxis; MSM: men who have sex with men; QALY: Quality-adjusted life year; ESRD: end-stage renal disease; ICER: incremental cost-effectiveness ratio

^*All costs reported in 2018 US dollars.

^**Values may not add to total due to rounding to five significant digits